Improvement in Overall Survival for Patients with Advanced Ovarian Cancer Treated Matching Caris Molecular Intelligence Profiling Recommendations
A recent study,1 published in 2016, has shown that patients with recurrent epithelial ovarian cancer, whose treatments were matched with the results of Caris Molecular Intelligence profiling recommendations, had a median overall survival nine months longer than those who received treatment that was reported by Caris Molecular Intelligence report to be associated with lack of benefit.
In this study, the researchers aimed to find out if patients who are treated in line with the results of their profiling report do better than those who are not treated in line with their profiling results. The study consisted of 224 patients from the Caris Registry with advanced stage epithelial ovarian cancers who were split into a matched (n=121) and unmatched (n=103) cohort. The matched cohort consisted of patients who had received at least one treatment that was identified by profiling as having potential benefit and no treatments that had been identified as having potential lack of benefit. The unmatched cohort consisted of patients who had received at least one treatment that had been identified as having potential lack of benefit.
Patients in the matched cohort had a median overall survival (OS) of 36 months, compared with patients in the unmatched cohort who had a median OS of 27 months.
Figure 1: Kaplan-Meier curve showing the increase in overall survival after profiling for patients in the matched cohort (green) vs. the unmatched cohort (red).
Profiling with Caris Molecular Intelligence also revealed prognostic trends with regards to the presence or absence of certain biomarkers. The researchers identified that patients with at least two of the following biomarkers: RRM1, ERCC1, TUBB3 and PGP had the poorest survival outcomes.
Researchers found that patients in the matched cohort received fewer lines of therapy than those in the unmatched cohort. Patients in the matched cohort received, on average, 3.88 lines of therapy compared with 5.02 lines of therapy administered, on average, to patients in the unmatched cohort. The researchers concluded from this that, “basing therapy on tumor profiling has an effect on selecting optimal therapies and improving OS.”1
The researchers concluded that this study, “suggests a potential predictive role of molecular profiling to avoid use of inactive therapies.”1
- A recent study has found that patients with advanced ovarian cancer who only received therapy matched to their Caris molecular profiling results had a median overall survival of 9 months longer than patients who received any unmatched therapies.
- Patients in the matched cohort, on average, received fewer lines of therapy (3.88 lines) than patients in the unmatched cohort (5.02 lines).
- The researchers also identified, through Caris Molecular Intelligence profiling, the presence of biomarkers prognostic of poorer survival outcomes.
1. Herzog TJ, Spetzler D, Xiao N, et al. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget. 2016; 7: 19840-9. Available from: [URL Link]
Page reviewed: 1 March 2018